October Pharma

مادة اعلانية

Latest Update: 23 July 2025 15:14 Abu Dhabi Time.

Market Status: Closed

OCPH

October Pharma

130.50

EGP

-2.070

-1.56%

Open

132.57

Prev Close

132.57

PX_VOLUME

2,637

MARKET CAP (M)

DAY RANGE

127.15 - 135.00

52 WEEKS

85.04 - 166.99

Stock Statistics

Yearly Change

31.46%

Listed Shares (Million)

12.00

Earnings Multiple

9.92

Average 30-day trading volume

2,261.26

Price-to-book ratio

2.52

Earnings Per Share

12.65

Previous Dividend Distribution

2.38

Dividend Yield

0.00%

Financial Summary

Quarterly
Annual

Income Statements

	Period Ending:	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023
Total Revenue		386.09	342.12	326.08	285.42	274.41	307.28	263.15
Gross Profit		174.54	139.67	131.11	120.96	133.78	141.12	133.72
Operating Income		112.74	85.07	80.67	71.33	79.69	89.10	84.99
Profit Margin		14.84	10.83	9.83	11.43	18.27	16.73	18.63

	Period Ending:	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Total Revenue		1,228.03	1,011.65	727.37	655.04	543.40
Gross Profit		525.52	498.29	356.90	323.12	250.90
Operating Income		316.76	308.82	203.40	195.54	144.86
Profit Margin		12.36	18.00	17.98	18.29	16.24

Balance Sheet

	Period Ending:	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023
Total Assets		1,442.58	1,413.84	1,469.26	1,329.25	1,242.70	1,138.09	1,097.10
Total Liabilities		815.96	844.49	820.64	712.67	603.03	548.55	558.96
Total Equity		626.63	569.35	648.62	616.58	639.67	589.54	538.14

	Period Ending:	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Total Assets		1,413.84	1,138.09	950.08	553.06	606.15
Total Liabilities		844.49	548.55	524.55	213.60	352.29
Total Equity		569.35	589.54	425.52	339.46	253.86

Cash Flows Statements - Coming Soon

* In Million of Egypt Pound

Reminder: The financial information on this website is delayed information that are originates from certified data providers in the financial markets, who retain the rights and intellectual property of this data, absolving ADMN of any responsibility.